2022
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
Fichtner ML, Hoarty MD, Vadysirisack DD, Munro-Sheldon B, Nowak RJ, O’Connor K. Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. PLOS ONE 2022, 17: e0264489. PMID: 35290370, PMCID: PMC8923450, DOI: 10.1371/journal.pone.0264489.Peer-Reviewed Original ResearchMeSH KeywordsAutoantibodiesComplement System ProteinsHumansMyasthenia GravisReceptors, CholinergicSeverity of Illness IndexConceptsAutoantibody titersComplement activityDisease activityMyasthenia gravisComplement pathwayAcetylcholine receptor autoantibodiesAutoimmune myasthenia gravisSecondary complement deficiencyClassical complement pathwayAChR autoantibodiesReceptor autoantibodiesClinical statusAutoimmune diseasesHealthy controlsComplement deficiencyPatients associatesStudy subjectsCandidate biomarkersDisease statusDisease severitySignificant associationDisease pathologyTitersAutoantibodiesPatients
2010
Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple Sclerosis
Klawiter EC, Piccio L, Lyons JA, Mikesell R, O’Connor K, Cross AH. Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple Sclerosis. JAMA Neurology 2010, 67: 1102-1108. PMID: 20837855, PMCID: PMC3051403, DOI: 10.1001/archneurol.2010.197.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMyelin oligodendrocyte glycoproteinCerebrospinal fluidClinical disabilityMS patientsCSF markersAntibody productionForms of MSProspective case-controlled seriesMyelin oligodendrocyte glycoprotein antibodyDiagnosis of MSImmunoglobulin G indexNoninflammatory neurologic diseasesRoutine CSF testingProgressive multiple sclerosisAcademic referral centerRelapsing-remitting MSRadiographic outcome measuresMagnetic resonance metricsCase-control seriesReferral centerAlbumin levelsIgG indexCSF testingGlycoprotein antibodies